[High-dose cytosine arabinoside and L-asparaginase in the treatment of refractory or recurrent acute non-lymphoblastic leukemia].
Sanz
M A
MA
Borrego
D
D
Martín-Aragonés
G
G
Martínez
J A
JA
Lorenzo
I
I
Sanz
G
G
Sayas
M J
MJ
Jarque
I
I
Pastor
E
E
Rafecas
J
J
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction
D003561:Cytarabine; D001215:Asparaginase
Arabinósido de citosina a altas dosis (Ara-C-AD) y L-asparaginasa (L-ASP) en el tratamiento de la leucemia aguda no linfoblástica refractaria o en recidiva.